Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Denali Therapeutics' Liabilities and Shareholders Equity fell 2739.95% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 1448.1%. This contributed to the annual value of $1.4 billion for FY2024, which is 1908.83% up from last year.
  • Denali Therapeutics' Liabilities and Shareholders Equity amounted to $1.1 billion in Q3 2025, which was down 2739.95% from $1.2 billion recorded in Q2 2025.
  • Denali Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $1.6 billion for Q1 2024, and its period low was $1.1 billion during Q3 2025.
  • Over the past 5 years, Denali Therapeutics' median Liabilities and Shareholders Equity value was $1.4 billion (recorded in 2024), while the average stood at $1.4 billion.
  • In the last 5 years, Denali Therapeutics' Liabilities and Shareholders Equity soared by 13323.48% in 2021 and then tumbled by 2739.95% in 2025.
  • Over the past 5 years, Denali Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $1.4 billion in 2021, then increased by 3.99% to $1.5 billion in 2022, then fell by 20.98% to $1.2 billion in 2023, then grew by 19.09% to $1.4 billion in 2024, then dropped by 23.18% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.